Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.33

-0.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biomaven	3/22/2006 10:23:45 AM
	Read Replies (2) of 52153

TELK is on sale this morning because of a dumb Bloomberg article: John Dorfman , president of Dorfman Investments in Boston, is a columnist for Bloomberg News. The opinions expressed are his own. His firm or its clients may own or trade investments discussed in this column. Beware Telik, KFX, Onyx Shares at 100 Times Sales: John Dorfman March 21 (Bloomberg) -- Investors are wild these days over Telik Inc., KFX Inc. and Onyx Pharmaceuticals Inc. Each of these companies sells for 100 times revenue or more. Over the past six years I have demonstrated in this column that investing in such stocks is usually a sucker's bet. ... I added a little to my stock and option position. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next